BioBlast Pharma, Ltd. (NasdaqGM: ORPN) is a clinical-stage biopharmaceutical company focused on the development of treatments for orphan diseases. The Company completed a successful IPO on July 30th that raised $35 million for the development of three technology platforms for the treatment of multiple related orphan diseases. The targeted disease areas were chosen based on strict criteria including clear unmet medical need and the existence of patient clusters to facilitate clinical trials. BioBlast is a capital efficient company that specializes in harnessing the capabilities of their partners at major medical centers in order to advance clinical trials.

Read More